Comparison of randomized controlled trials of different preparations of LMWH vs VKA for the long-term management of cancer-associated thrombosis. Recurrent VTE (A), major bleeding episodes (B), and mortality (C) during the anticoagulant treatment period are shown for the CLOT²⁴  (6 months of dalteparin or VKA), LITE²⁵  (3 months of tinzaparin or warfarin), and CANTHANOX²⁷  (3 months of enoxaparin or warfarin) trials. NS, not statistically significant.